Agomab Therapeutics NV, headquartered in Ghent, Belgium, is a clinical-stage biopharmaceutical company dedicated to pioneering treatments for fibro-stenotic and regenerative diseases. Established in 2017, the company leverages its deep understanding of growth factor biology to develop a pipeline of small molecules and antibodies designed to modulate pathways that drive fibrosis and tissue repair. Agomab’s therapeutic strategy focuses on two primary pathways: the Transforming Growth Factor beta (TGF-β) pathway and the Hepatocyte Growth Factor (HGF) pathway. Their lead clinical candidate, AGMB-129, is a gut-restricted, small-molecule inhibitor of ALK5 (TGF-β receptor 1) currently being evaluated for the treatment of fibrostenotic Crohn’s disease. By inhibiting ALK5 locally in the gastrointestinal tract, the company aims to prevent and reverse the fibrotic complications that often lead to surgery in Crohn's patients. In addition to its gastrointestinal programs, Agomab is developing AGMB-447, an inhaled ALK5 inhibitor for Idiopathic Pulmonary Fibrosis (IPF), and AGMB-101, a MET-agonistic antibody designed for regenerative applications in organ failure. The company’s approach combines precision medicinal chemistry with a focus on high unmet medical needs in chronic inflammatory conditions. Led by CEO Tim Knotnerus, Agomab has secured significant backing from prominent life sciences investors and successfully transitioned to a public company on the NASDAQ exchange to fund its expanding clinical trials and research initiatives.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!